Policy / Regulatory

China's National Joint Procurement Office Disqualifies Eugia Pharma and JSC "Farmak" Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules
Centralized procurementVBP (voluem-based procurement)

China’s National Joint Procurement Office Disqualifies Eugia Pharma and JSC “Farmak” Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules

The National Joint Procurement Office for Drugs announced that two selected companies in China's national centralized drug procurement program have been disqualified and placed on the "violation list" after failing…

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US

Chongqing Unveils Three-Year Public Health Action Plan Draft for Public Feedback

GlaxoSmithKlineGSK

FDA Addresses Looming Migraine Treatment Shortage with Tonix Pharmaceuticals Commitment

NMPA

NMPA Drafts Guidelines for Supervising Online Drug Exchange Platforms

CDEGreater Bay Area

CDE’s 2022 Drug Review Report: A Year of Pandemic Response and Regulatory Milestones

Show More